AdvertiseDonate
☰ SectionsThe latest from the cities that shape the country.
Wire Authority · 3970 Post Road, Warwick, RI 02886

FDA Case Against Drug Importers Relies on CEO Who Became an Informant

A criminal case against a Canadian healthcare company has emerged from an investigation into a peer firm, with the latter's CEO providing key testimony and evidence.

By News Media House Staff ·

Illustration for: FDA Case Against Drug Importers Relies on CEO Who Became an Informant
Illustration generated for this article, not a news photograph.

A federal criminal case targeting an alleged illegal prescription drug operation and its two top leaders has revealed an unusual dynamic in the enforcement of U.S. drug import laws. The case features a notable informant: the chief executive officer of a peer company that authorities state was committing the same violations. This development marks the first criminal prosecution by U.S. authorities against a company involved in the alternative funding program industry, a sector known for promising to lower or eliminate high prescription drug costs for Americans.

The targets of the charges are John Thomas Howard and his brother Bob Howard, the treasurer and president respectively of CANARX, a Canadian healthcare company based in Windsor, Ontario. John Howard was arrested on November 8 in the tunnel connecting Detroit and Canada. He faces charges of smuggling, conspiracy, and importing a misbranded drug for patient use in the United States. His brother, Bob Howard, remains wanted on similar charges as of last week, according to court records.

The investigation originated from a tip regarding ScriptSourcing, a Florida-based healthcare operation. Dustin Dobbs, a special agent with the FDA's Office of Criminal Investigations, detailed the case in a 35-page affidavit dated October 29 and unsealed last week. ScriptSourcing marketed its international prescription program to self-funded employer health plans. Its founder and CEO, Gary Becker, was described as having over 30 years of experience as a health insurance and risk management consultant.

ScriptSourcing had been under FDA observation since at least 2022 for potential violations. In August 2025, Agent Dobbs posed as a potential client and inquired about the company's FDA compliance. A ScriptSourcing employee replied that the company was compliant, possessed more than 2,000 name brand specialty medications, and worked with over 3,000 self-funded health plans. However, the agency also learned of two incidents that year where medications from the program allegedly harmed patients. One patient was hospitalized for a small bowel obstruction after using misbranded Mounjaro sourced via a Canadian pharmacy, while another was seriously injured by a counterfeit medication.

Facing increased scrutiny, Gary Becker turned his attention to the Howard brothers. By May 2026, Becker had become a cooperating witness for the government. He informed the FDA that he had done business with CANARX on drug importation and that the company had provided him with a roadmap for operations. ScriptSourcing subsequently provided the FDA with a spreadsheet of financial transactions with CANARX spanning from 2021 to 2026. The document indicated that approximately 16,549 prescription drugs had been dispensed through these channels.

Between June and July 2026, Becker engaged in several recorded phone calls with the Howard brothers regarding foreign importations. Agent Dobbs noted in the affidavit that these calls demonstrated John Howard was aware of the routes for importing drugs from Canada to the U.S. and had attempted to adapt them to fit CANARX's program. The calls also showed that both brothers knew the drugs were not legally allowed to enter the United States.

At the time the evidence was provided, CANARX had shipments in progress, including a package of Neupro, an FDA-regulated drug used to treat Parkinson's disease and restless legs syndrome. Joseph Morris, general counsel for CANARX, stated last week that the Howard brothers deny all charges and intend to defend themselves vigorously, expecting to be vindicated in court. Previously, Morris had told CNBC that the business was operating legally and was confident in the safety of its prescriptions.

The controversy extends beyond criminal charges into civil litigation. Gilead Sciences filed a lawsuit in December 2024 alleging that several companies, including CANARX, illegally imported its HIV drug Biktarvy. Gilead welcomed the government's recent efforts to hold accountable those who may put patients at risk. Gary Becker's attorney confirmed that ScriptSourcing is no longer in business but declined to comment further. The FDA did not respond to a request for comment on the specifics of the affidavit.

The case highlights the tension between the AFP business model and federal regulations. While proponents argue that individual importation for personal use is allowable under U.S. law, authorities contend that these corporate operations go too far. The unregulated nature of drugs intended for foreign markets poses risks of counterfeit products and health hazards, a concern central to the FDA's ongoing enforcement actions.

Originally published by News Media House

More News · National news · Report a business · Got a Story?

Get Wire Authority in your inboxThe latest from the cities that shape the country. Free, a few times a week, unsubscribe any time.

Related stories

Latest stories

  1. Philadelphia 76ers Overcome Large Deficit to Halt Orlando Magic Streak
  2. Anthropic completes record-breaking IPO raising over $100 billion
  3. Airbnb Reopens the Raichand Mansion for K3G 25th Anniversary
  4. Record 589 million children living in conflict zones as humanitarian access is blocked
  5. New HBO Documentary Details Rape Allegations Against Andrew Tate
Get Wire Authority in your inboxThe latest from the cities that shape the country. Free, a few times a week, unsubscribe any time.